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Steroid-resistant nephrotic syndromeHuman COQ6 encodes a monooxygenase which is responsible for the C5-hydroxylation of the quinone ring of
coenzyme Q (CoQ). Mutations in COQ6 cause primary CoQ deﬁciency, a condition responsive to oral CoQ10
supplementation. Treatment is however still problematic given the poor bioavailability of CoQ10. We employed
S. cerevisiae lacking the orthologous gene to characterize the two different human COQ6 isoforms and the
mutations found in patients. COQ6 isoform a can partially complement the defective yeast, while isoform
b, which lacks part of the FAD-binding domain, is inactive but partially stable, and could have a regulatory/
inhibitory function in CoQ10 biosynthesis. Most mutations identiﬁed in patients, including the frameshift
Q461fs478X mutation, retain residual enzymatic activity, and all patients carry at least one hypomorphic allele,
conﬁrming that the complete block of CoQ biosynthesis is lethal. These mutants are also partially stable
and allow the assembly of the CoQ biosynthetic complex. In fact treatment with two hydroxylated analogues
of 4-hydroxybenzoic acid, namely, vanillic acid or 3-4-hydroxybenzoic acid, restored the respiratory growth of
yeast Δcoq6 cells expressing the mutant huCOQ6-isoa proteins. These compounds, and particularly vanillic
acid, could therefore represent an interesting therapeutic option for COQ6 patients.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Coenzyme Q (CoQ) is a small lipophilic molecule comprised of a
quinone ring and of a poly-isoprene tail of variable length: 6 units in
the yeast Saccharomyces cerevisiae (CoQ6) and 10 in humans (CoQ10).
CoQ is a key component of the respiratory chain, where it acts as an
electron transporter between complexes I and II and complex III. CoQ
also acts as an antioxidant and is a modulator of lipid β-oxidation and
apoptosis [1].ase; CoQ, coenzyme Q; CoQ10,
3,4 diHB, 3,4 dihydroxybenzoic
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.
. Open access under CC BY-NC-ND license.In S. cerevisiae, synthesis of CoQ requires a set of at least nine genes
(COQ genes), all of them with human orthologues. The precursor of
quinone ring is 4-hydroxybenzoate (4HB), a catabolite of tyrosine,
which is modiﬁed by amultienzymatic complex (CoQ complex) located
on the mitochondrial inner membrane, on the matrix side [2]. This
complex contains the majority of the enzymes involved in CoQ bio-
synthesis, although its exact composition is still under investigation.
Mutations in COQ genes cause primary CoQ deﬁciency, a clinically
heterogeneous group of disorders. One peculiarity of CoQ deﬁciency is
that patients respond to oral administration of CoQ10. However,
treatment is still problematic for the relatively low bioavailability of
CoQ10 due to its high hydrophobicity. This has stimulated different
lines of research aimed at increasing the bioavailability of CoQ10 or at
searching other molecules that could be beneﬁcial in this disease [3].
Mutations in COQ6 cause a form of steroid-resistant nephrotic
syndrome with a variable degree of neurologic involvement [4]. COQ6
encodes for a monooxygenase comprised in the CoQ complex, respon-
sible for the C5-hydroxylation of the quinone ring. Vanillic acid (VA)
and 3,4-dihydroxybenzoic acid (3,4 diHB), two analogues of 4HB that
carry either a methoxyl or a hydroxyl group in position 5 of the ring,
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structurally stable, Coq6 alleles, which allow the formation of the CoQ
complex [5].2. Patients and methods
2.1. Patients and mutations
Patients and mutations have been reported previously [4]. In brief
A353D and G255Rwere found in the homozygous state in two kindreds
each. Q461fs478X andW447Xwere found in compound heterozygosity
in a single family. We included in the analysis a novel variant, Y412C,
which was found in the heterozygous state in a patient with SRNS in
whom a second mutation could not be detected.2.2. Construction of yeast expression vectors
The coding sequence of yeast COQ6 (yCOQ6) gene and the two
human COQ6 isoforms were ampliﬁed from yeast genomic DNA or
from cDNA (primers are available upon request) and cloned into the
centromeric pCM189 yeast expression vector. Mutants were then
generated using the QuikChange II site directed mutagenesis kit
(Stratagene, La Jolla, CA, USA).
To replace the cytochrome c1 (CYC1) promoter of pCM189::yCOQ6
with the yCOQ6 endogenous promoter a fragment including the 5′UTR
region of yCOQ6 and the ﬁrst 844bp was ampliﬁed from yeast genomic
DNA (primers are available upon request) and cloned into the pCR4-
TOPO vector (Invitrogen, Carlsbad, CA, USA). A SacI–Msc I fragment
from this construct was subcloned into the wild-type and mutated
versions of pCM189::yCOQ6 after similar digestion. The correctness
of all constructs was conﬁrmed by direct sequencing.2.3. Yeast strains, media, transformations and CoQ measurement
The Δcoq6 strain Y07287 (MATa; his3Δ1; leu2Δ0; met15Δ0; ura3Δ0;
YGR255c::kanMX4) was purchased from the Euroscarf Consortium
(Frankfurt, Germany). Rich YPD (1% yeast extract, 2% peptone and 2%
glucose), YPG (1% yeast extract, 2% peptone and 3% glycerol) and
selective SM GLU HLM (0.17% yeast nitrogen base without amino
acids, 0.5% ammonium sulphate, 2% glucose or galactose) and LG-
pABA HLM medium were prepared as described [5]. Selective
media were supplemented with amino acids to cover the yeast
auxotrophies except for uracil which is carried by the plasmids.
VA and 3,4 diHB were prepared as described [5]. All yeast DNA
transformations were performed with the PEG-lithium acetate method
as previously reported [6,7]. CoQ was measured as previously described
[5,8].2.4. Molecular modelling and bioinformatic analyses
Human COQ6-isoa sequencewas alignedwith a published alignment
based on structure superpositions of different members of the aromatic
hydroxylases family [9] using ClustalX and the alignment was curated
by hand in order to favor gaps outside secondary structure elements.
This alignment was then used inModeler with Pseudomonas ﬂuorescens
para-hydroxybenzoate hydroxylase (Protein Data Bank code 1PBE) as
target. Standard setup was used but for six regions where alpha-helices
constraints were forced (45–60, 73–83, 220–227, 293–299, 319–
328 and 397–401). These human COQ6 fragments overlap existing
alpha helices found in pHBH and contiguous insertions. In silico
analysis of the pathogenicity of the Y412C mutation was performed
as described [10].3. Results
3.1. COQ6 isoform a but not isoform b can partially complement Δcoq6
yeast
Human COQ6 encodes for at least two isoforms (huCOQ6-isoa and
huCOQ6-isob) that differ for the transcription initiation site and for the
splicing of exon 3 (Fig. 1A). huCOQ6-isoa is far more abundant than
huCOQ6-isob [4]. In yeast there is only one isoform and its deletion
causes the loss of the ability to synthesize CoQ and to grow on non-
fermentable carbon sources [11]. We expressed the two human
isoforms using a centromeric expression vector (pCM189) with the
cytochrome c1 (CYC1) promoter, in S. cerevisiae BY4741Δcoq6 haploid
strain, and checked the ability of the transformants to grow on a non-
fermentable medium (YPG contains glycerol) which requires a
functional respiratory chain. Only huCOQ6-isoa restored respiratory
growth of the Δcoq6 yeast strain (Fig. 1B). The analysis of CoQ content
of the different transformants grown in minimal medium revealed
that the huCOQ6-isoa achieved levels of CoQ about 2.5% of those
obtained with the yeast gene, while no detectable amount of CoQ was
produced with huCOQ6-isob (Fig. 1C). This system is over 10 times
more efﬁcient than the one previously published, in which the wild
type human gene could achieve levels of CoQ of just 0.2% of what
could be obtained with the wild type yeast gene [4]. By the same
analysis we detected only a very limited amount of 3-hexaprenyl-4-
hydroxyphenol (4HP6) in huCOQ6-isoa transformants (Fig. 1D), indi-
cating that the human protein is not rate limiting for C5-hydroxylation
and that the low level of complementation is probably due to an
inefﬁcient stabilization of the CoQ complex [5].
3.2. Missense mutations found in patients with SRNS affect COQ6 function
Because the complementation observed with this new huCOQ6-isoa
construct is more efﬁcient than the one obtained with the system
employed in our previouswork [4],we constructed plasmids expressing
huCOQ6-isoa with the different mutations found in patients, including
the novel Y412C, and repeated the growth assay. W447X, G255R, and
Y412C mutants did not complement the respiratory growth defect of
the Δcoq6 yeast strain (Fig. 1E). These data indicate that Y412C is a
pathogenic COQ6 allele even though its role in determining the patient’s
phenotype is still under investigation. Interestingly, the bioinformatic
analysis could not reliably predict the consequences of this variant.
Some residual growth was observed with A355D and, surprisingly,
with the frameshift Q461fs478X allele (Fig. 1E).
3.3. Most human COQ6 mutations are hypomorphic
Since heterologous expression may fail to detect residual activity of
mutated alleles due to the relatively low complementation efﬁciency
observed with the human gene, we modeled the “human” mutations
on the corresponding residues of the yeast gene (Fig. 2A and B). In the
case of the Q461sf478X mutation, we expressed both a form with a
truncation at position 469 (M469X) and a form with the 18 extra
abnormal amino acids generated by the frameshift mutation in the
human gene (Fig. 2B). In yeast Coq6, a phenylalanine (F420) is found
in place of the corresponding human Y412. We therefore synthesized
two different constructs: F420Y and F420C. Bothwild type andmutated
alleles were expressed either under the control of the strong CYC1
promoter or the physiological S. cerevisiae COQ6 promoter. With the
CYC1 promoter, only the nonsense mutation F455X (corresponding to
human W447X) failed to complement the respiratory growth defect
of the Δcoq6 strain, while all the other alleles restored normal yeast
growth and CoQ content (not shown). When the endogenous yeast
COQ6 promoter drove the expression, the cells displayed a variable
reduction in growth (Fig. 2C) and a more evident defect in CoQ content
(Fig. 2D). As expected, the F420Y construct displayed normal growth
Fig. 1. (A) The two principal isoforms of human COQ6. Exon 2 is translated by a different reading frame in isob (in gray). (B) Growth assay of Δcoq6 cells transformed with either yCOQ6,
huCOQ6-isoa, huCOQ6-isob or an empty pCM189 vector. Cells were plated onto respiratory rich medium (YPGLY) or on SM GLU–URA as positive control. (C) CoQ6 and demethoxy-
coenzyme Q6 (DMQ6) amounts in Δcoq6 cells expressing either yCoq6, huCOQ6-isoa or huCOQ6-isob. Cells were grown in YNB–pABA 2% galactose containing 10 μM 4HB. The results
are the average of 4 independent experiments. (D) Representative electrochromatogram of lipid extracts from Δcoq6 cells expressing either yCOQ6 (1 mg of cells) or huCOQ6-isoa
(6mg of cells). The elution position of the CoQ4 standard, of DMQ6, 4HP6 and CoQ6 are indicated. (E) Growth assay of Δcoq6 cells expressing huCOQ6-isoa wild type or carrying different
mutations on the same media as in (B).
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A353D, Y412C and Q461sf478X mutations are hypomorphic since the
corresponding yeast Coq6 mutants display residual activity.
3.4. 4-Hydroxybenzoate analogues can restore growth in yeast Δcoq6 cells
expressing human mutant alleles
When added to the growth medium, two analogues of 4HB, VA and
3,4 diHB, can bypass the CoQ deﬁciency of yeast Δcoq6 cells expressing
enzymatic inactive but structurally stable, Coq6 protein [5]. We ﬁrst
plated yeast Δcoq6 expressing huCOQ6-isoa and huCOQ6-isob on
respiratory media containing either VA or 3,4 diHB. In the case of
huCOQ6-isoa, VA did not further increase the growth, while it allowed
partial recovery of growth in the case of huCOQ6-isob compared to
medium with 4HB (Fig. 3A). A similar pattern was observed with 3,4
diHB (not shown). In agreement with previous data [5], no growth
was observed for the strain transformed with the empty vector. Wethen measured the CoQ production after culturing in the presence of
VA. Yeast expressing huCOQ6-isoa achieved CoQ levels about 20% of
those obtained with yCOQ6, while strains expressing huCOQ6-isob
produced about 11% of CoQ compared to the yeast gene (Fig. 3B).
Finally, we tested the effect of VA or 3,4 diHB in yeast expressing
individual human mutant alleles. We detected a partial rescue of the
phenotype in the presence of the analogues in all cases. VA seemed
more efﬁcient than 3,4 diHB, with effects already evident at 0.1 mM
(Fig. 3C). These results indicate that themutations impair the enzymatic
activity of COQ6, but still allow formation of the CoQ complex.
Interestingly this was observed also with the W447X truncating
mutation, indicating that this should not be considered a null allele.
3.5. Molecular modeling of the human mutations
Because the structure of human COQ6 is not available, the protein
was modeled on Pseudomonas ﬂuorescens para-hydroxybenzoate
Fig. 2. (A)Missensemutations in huCOQ6-isoa and the corresponding residues in yCoq6. (B) Schematic representation of the huCOQ6-isoa constructs carrying theW447X andQ461fs478X
mutations and their counterpart in yCOQ6.Growth assay (C) and CoQ6 levels (D) inmitochondria fromΔcoq6 cells expressing different yCoq6mutants under the control of the endogenous
yeast promoter.
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sequence (that has no equivalent in pHBH). As depicted in Fig. 4A,
residues Y412 and A353 interact with residues that belong to the
classical Rossman fold which is implicated in FAD binding. Mutations
probably affect the activity of huCOQ6-isoa by perturbing the binding/
positioning of FAD. The substrate of Coq6 is prenyl-4HB. Based on the
position of 4HB in the structure of pHBH [11], we ﬁnd a similar pocket
in huCOQ6-isoa (Fig. 4B). G255 is located in the active site pocket at
about 1.7 nm from 4HB binding site and deﬁnes part of its surface
(Fig. 4B). The substitution of the glycine with an arginine reduces
signiﬁcantly the volume of the pocket and adds positive charges that
may hinder the binding of the hydrophobic substrate. W447 and Q461
residues are located in the C-terminus of the protein. As depicted in
Fig. 4B and C, the C-terminal tail forms part of the surface of active
pocket site. Alterations of this region are likely to cause a perturbation
of the active site.4. Discussion
Human COQ6 is transcribed in at least two isoforms which differ for
the N-terminal portion. We have previously shown that huCOQ6-isoa
can restore the ability of Δcoq6 yeast to grow on a nonfermentable
carbon source, although the amount of CoQ synthesized by the cells
was very low [4]. We have now developed a more efﬁcient system
based on pCM189 vectors which allows a higher CoQ production (2.5%
of yeast versus 0.2%). It should be noted that often complementation
of yeast deletion mutant with their human orthologues results in low
levels of CoQ6 production compared to the human gene. Human
COQ8-ADCK3 yielded less than 0.5% CoQ6 compared to the yeast gene
when expressed from a multicopy plasmid [12].Yeast expressing huCOQ6-isoa do not display signiﬁcant 4HP6
accumulation, indicating a reduced ability to stabilize the CoQ complex
rather than a catalytic problem. In fact, expression of a stable but
catalytically inactive Coq6 or overexpression of Coq8 results in
signiﬁcant accumulation of 4HP6 [5].
As expected (it lacks a signiﬁcant portion of the FAD binding
domain) huCOQ6-isob is enzymatically inactive; nevertheless, it
appears to be able partially stabilize the CoQ biosynthetic complex, as
both VA and 3,4 diHB can restore CoQ synthesis in Δcoq6 yeast
expressing this isoform. These data imply that huCOQ6-isob is
transported into mitochondria. We speculate that in human cells it
could compete with huCOQ6-isoa for assembly into the CoQ complex
and could therefore play a regulatory/inhibitory role in CoQ biosynthesis.
Further work is needed to address this issue.
Mutations in human COQ6 cause a multisystem disorder with a
predominant renal involvement and variable neurologicalmanifestations.
Our data show that with the exception of the W447X mutant, all other
alleles retain residual activity, including the frameshift mutant
Q461sf478X, which displayed signiﬁcant residual growth as documented
in Figs. 1E and 2C and D. This is consistent with the fact that the clinical
phenotype in the patient who harbored this mutation in trans with
W447X was not signiﬁcantly different from patients who carried
missense mutations. In fact, all patients harbored at least one hypo-
morphic allele, in agreement with the notion that a complete block in
CoQ biosynthesis is incompatible with life [13,14]. Interestingly, when
we introduced the mutation into the yeast gene, the CoQ content was
only slightly lower in the M469X allele compared to the form with the
18 abnormal C-terminal amino acids, suggesting that despite being
important for the formation of the catalytic site the eight C-terminal
amino acids of COQ6, which are conserved only in higher vertebrates
are not that crucial for the stability and the functionality of the enzyme.
Fig. 3. (A) Growth assay of Δcoq6 cells expressing huCOQ6-isoa, huCOQ6-isob and yCoq6 on LG-pABA medium containing either 10 μM 4HB or 0.1mM VA. (B) CoQ levels in Δcoq6 cells
expressing huCOQ6-isoa, huCOQ6-isob and yCoq6 grown in YNB–pABA 2% galactose with 1 mM VA. (C) Growth assay in LG-pABA non-fermentable medium of Δcoq6 cells expressing
human COQ6 mutants in the presence of VA or diHB.
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pathogenicity of COQ gene variants, which will be particularly useful in
the upcoming yearswhen exome sequencingwill become routine clinical
practice.
We ﬁnally tested if VA and 3,4 diHB could rescue CoQ deﬁciency in
yeast expressing the human COQ6 mutants. In all cases (including the
W447X) we noted partial recovery of growth in non-fermentable
media, indicating that 3,4 diHB and especially VA can bypass the CoQ
biosynthetic defect caused by these mutations. This result suggests
that these mutations impair mostly COQ6 catalytic activity rather than
its structural stability. In fact, Y412C and A353D seem to perturb the
binding of the FAD, while G255R, W447X and Q461fs478X are likely
to cause a rearrangement of the active site pocket. Direct proof of this
by Western blot could not be achieved because of the poor quality of
the available COQ6 antibodies that recognize multiple aspeciﬁc signals
in yeast.
The response of these mutants to VA could have important
implications for patient therapy. In fact, although patients respond
to CoQ supplementation, very high doses of the compound are required,
because of its low bioavailability and its limited delivery tomitochondria.VA is non-toxic (it is commonly used as a ﬂavoring agent by the food
industry), has a good oral bioavailability [15], and acts by reactivating
endogenous CoQ biosynthesis. This has critical therapeutic implications
since it has been shown that in C. elegans coq-3 mutants reactivation of
endogenous biosynthesis was much more effective than exogenous CoQ
supplementation [16]. In fact endogenously produced CoQ will be
delivered to the appropriate subcellular compartments, while with
exogenous supplementation the distribution of CoQ is not controlled
and CoQ may have difﬁculties to efﬁciently reach the mitochondrial
inner membrane. We still have no idea of what could be the potential
dangers in the long or very long term (the treatment must be continued
lifelong) of having an excess of CoQ in other cellular compartments.
Furthermore, the QH2/Q ratio can be changed in these cells contributing
to a new redox environment that can produce higher reactive oxygen
species [17]. Restoration of endogenous biosynthesis, but not CoQ
supplementation, would contribute to rescue the original balance.
Although future studies are clearly needed to address the safety and
efﬁcacy of VA in patients, this approach could represent a major
improvement in the treatment of patients with CoQ deﬁciency due to
COQ6mutations.
Fig. 4. (A) A353 and Y412 and their side chains. Inmagenta the conserved residues that belong to the Rossman fold is implicated in FAD binding. (B) Contribution of G255 (yellow) and of
the residues afterW447 (green) to the surface of the active site pocket. Cofactor and substrate are shown in stick representation. (C) Overall representation of huCOQ6-isoa with 4HB and
FAD, the different point mutants and of the C-terminal region comprising residues after W447 (green).
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